Image source: Shutterstock

Highlights

  • Morgan Stanley upgrades Medibank to "overweight" and sets Street-high target of AUD 5.57
  • Stock hits record high of AUD 5.31, marking largest intraday gain since February 27
  • Analysts point to sustainable margins amid lower claims and reduced market competition

Shares of Medibank Private Ltd (ASX: MPL) surged as much as 5.2% to a record AUD 5.31 on Monday, after Morgan Stanley upgraded the Australian health insurer to “overweight” from “equal-weight” and raised its price target to AUD 5.57, the highest among analysts tracked.

The stock was one of the top gainers on the ASX200 index (AXJO), marking its largest single-day percentage increase since February 27. At last check, shares were up 4.1%, extending year-to-date gains to 38.3%.

Morgan Stanley cited multiple reasons behind the upgrade, including what it sees as Medibank’s advantageous positioning in the current health insurance landscape. The bank said the insurer is well-placed to maintain sustainable margins due to a combination of benign claims trends and a reduction in competitive pressures across the private health market.

The analysts also noted that Medibank's transition toward a broader health services model could attract higher valuation multiples over time. This strategic shift is seen as a differentiating factor in an environment where high-quality, defensive growth opportunities in the financial sector remain limited.

"Given current market dynamics, MPL may continue to see valuation re-rating as investors favour its earnings stability and margin visibility," the note said.

Morgan Stanley’s target of AUD 5.57 reflects a more bullish outlook compared to peers, implying potential upside from current levels. While risks remain—particularly related to regulatory oversight and claims volatility—the bank believes these are currently outweighed by supportive sector trends.

Medibank’s recent outperformance has set it apart from other financial sector names on the ASX, as investors rotate into defensive plays amid macroeconomic uncertainty. With cost pressures stabilising and competitive intensity easing, the insurer may benefit from an extended period of earnings predictability, according to Morgan Stanley.

Despite the share price rally, the upgrade suggests room remains for further upside, contingent on continued margin stability and favourable sector conditions. The market will be watching closely to see if Medibank can maintain its momentum through the next earnings cycle.